Pleural Dynamics was founded on a simple but urgent realization: patients with recurrent pleural effusions deserve a better way to manage their condition. In 2020, an Interventional Pulmonologist–Inventor and a seasoned Engineering Leader combined more than 25 years of clinical expertise and medical device innovation to pursue an intervention that could improve patient care—clinically and meaningfully. Their collaboration led to the development of ACES™ (Automatic Continuous Effusion Shunt), which received U.S. FDA clearance in 2023. Alongside commercial launch, the company initiated the ACES Study for Aseptic Pleural Effusion (NCT06210685) to evaluate real-world performance. Early clinical results have been significant. The device has achieved a 96% technical success rate and delivered up to a 94% reduction in pleural effusion volume—with no daily maintenance requirement.^1,2 Patient-reported outcomes further 
underscore its impact, with many saying that ACES treatment has “given them their lives back.”